Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis

Oncologist

Volumn 15, Issue 11, 2010, Pages 1164-1168

  Pusztai, Lajos ^a   Viale, Giuseppe ^b   Kelly, Catherine M ^a   Hudis, Clifford A ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; TUMOR BIOPSY;

BREAST NEOPLASMS; DIAGNOSIS; FALSE NEGATIVE REACTIONS; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; SELECTION BIAS;

EID: 78649959817     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0059     Document Type: Article

References (27)

1. Osborne CK. Heterogeneity in hormone receptor status in primary and met-astatic breast cancer. Semin Oncol 1985;12:317-326.
2. Li BD, Byskosh A, Molteni A et al. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994;57:71-77.
3. Spataro V, Price K, Goldhirsch A et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-740.
4. Simon R, Nocito A, Hübscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-1146.
5. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983;52:479-485.
6. Guarneri V, Giovannelli S, Ficarra G et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. The Oncologist 2008; 13:838-844.
7. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
8. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-1958.
9. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-1504.
10. Amir S, Ooi WS, Simmons C et al. Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clin Oncol 2008;20:763-768.
11. Aitken SJ, Thomas JS, Langdon SP et al. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2009 10.1093/annonc/mdp427.
12. Vincent-Salomon A, Pierga JY, Couturier J et al. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of27cases: A possible tool for anti-HER2 therapy management? Br J Cancer 2007;96:654-659.
13. Neubauer H, Gall C, Vogel U et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 2008;28: 1797-1804.
14. Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cy-tokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007; 25:5194-5202.
15. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009;15:842-844.
16. Gruvberger S, Ringnér M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-5984.
17. Pusztai L, Ayers M, Stec J et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003;9:2406-2415.
18. Weigelt B, Glas AM, Wessels LF et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 2003;100:15901-15905.
19. Lacroix M, Toillon RA, Leclercq G et al. Stable 'portrait' of breast cancer during, progression: Data from biology, pathology and genetics. Endocr Relat Cancer 2004;11:497-522.
20. Bernards R, Weinberg RA. A progression puzzle. Nature 2002;418:823.
21. Shah SP, Morin RD, Khattra J etal. Mutational evolutionina lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
22. Rhodes A, Jasani B, Barnes DM et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: Interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125-130.
23. Rdiger T, Höfler H, Kreipe HH et al. Quality assurance in immunohisto-chemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873-882.
24. Goldstein NS, Ferkowicz M, Odish E et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 2003;120:86-92.
25. Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001;115:44-58.
26. Miller K, Ibrahim M, Barnett S et al. Technical aspects of predictive and prognostic markers in breast cancer: What UK NEQAS data shows. Curr Diagn Pathol 2007;13:135-149.
27. Alred DC. Commentary: Hormone receptor testing in breast cancer: A distress signal from Canada. The Oncologist 2008;13:1134-1136.